Symbols / INMB $1.35 +3.05%
INMB Chart
About
INmune Bio Inc., a clinical-stage immunology company, focuses on developing drugs to reprogram the patients innate immune system to treat disease in the United States. It intends to develop and commercialize product candidates to treat hematologic malignancies, solid tumors, and chronic inflammation. The company's development programs include INKmune, which is in Phase 1 for the treatment of patients with high-risk myelodysplastic syndrome; and INB03, which is in Phase II for the treatment of breast cancer. It provides XPro1595 for the treatment of Alzheimer's disease and treatment resistant depression; and CORDstrom, a cell suspension for intravenous infusion or injection comprising aseptic, allogeneic, and pooled HucMSCs. It has license agreements with Xencor, Inc.; Immune Ventures, LLC; and University of Pittsburg. INmune Bio Inc. was incorporated in 2015 and is headquartered in Boca Raton, Florida.
Fundamentals
Scroll to Statements| Sector | Healthcare | Industry | Biotechnology | Market Cap | 35.89M |
| Enterprise Value | 9.24M | Income | -49.89M | Sales | 50.00K |
| Book/sh | 0.95 | Cash/sh | 1.04 | Dividend Yield | — |
| Payout | 0.00% | Employees | 13 | IPO | — |
| P/E | — | Forward P/E | -1.72 | PEG | — |
| P/S | 717.80 | P/B | 1.41 | P/C | — |
| EV/EBITDA | — | EV/Sales | 184.72 | Quick Ratio | 4.11 |
| Current Ratio | 4.17 | Debt/Eq | 4.26 | LT Debt/Eq | — |
| EPS (ttm) | -2.08 | EPS next Y | -0.78 | EPS Growth | — |
| Revenue Growth | — | Earnings | 2026-03-31 | ROA | -50.59% |
| ROE | -155.77% | ROIC | — | Gross Margin | 100.00% |
| Oper. Margin | -697.24% | Profit Margin | 0.00% | Shs Outstand | 26.59M |
| Shs Float | 20.61M | Short Float | 18.74% | Short Ratio | 9.57 |
| Short Interest | — | 52W High | 11.64 | 52W Low | 1.16 |
| Beta | 0.85 | Avg Volume | 412.77K | Volume | 208.14K |
| Target Price | $7.00 | Recom | Strong_buy | Prev Close | $1.31 |
| Price | $1.35 | Change | 3.05% |
Valuation Models
Price estimates from analyst targets and simple models.
1. Analyst consensus
$7.00
Mean price target
2. Current target
$1.35
Latest analyst target
3. DCF / Fair value
$-13.04
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$1.35
Low
$4.00
High
$9.00
Mean
$7.00
Latest analyst rating changes
| Date | Action | Analyst | Rating Change | Price Target |
|---|---|---|---|---|
| 2026-03-11 | up | LUCID CAPITAL MARKETS | Neutral → Buy | $9 |
| 2025-07-02 | main | Maxim Group | Buy → Buy | $8 |
| 2025-07-01 | down | BTIG | Buy → Neutral | — |
| 2025-07-01 | down | Scotiabank | Sector Outperform → Sector Underperform | $1 |
| 2025-02-13 | main | Maxim Group | Buy → Buy | $30 |
| 2025-02-11 | main | Scotiabank | Sector Outperform → Sector Outperform | $23 |
| 2023-06-01 | init | Baird | — → Outperform | $16 |
| 2022-05-24 | main | BTIG | — → Buy | $14 |
| 2022-05-24 | down | B. Riley Securities | Buy → Neutral | $7 |
| 2022-01-24 | main | B. Riley Securities | — → Buy | $20 |
| 2021-04-21 | init | B. Riley Securities | — → Buy | $29 |
| 2020-11-09 | main | HC Wainwright & Co. | — → Buy | $15 |
| 2020-09-01 | init | BTIG | — → Buy | $23 |
| 2020-07-15 | main | HC Wainwright & Co. | — → Buy | $20 |
| 2020-05-15 | reit | HC Wainwright & Co. | — → Buy | $8 |
| 2020-03-12 | main | HC Wainwright & Co. | — → Buy | $8 |
| 2019-12-19 | init | Roth Capital | — → Buy | $13 |
| 2019-08-21 | init | HC Wainwright & Co. | — → Buy | $12 |
| 2019-03-19 | init | Maxim Group | — → Buy | — |
- Alzheimer’s therapy XPro1595 nears key trial as INmune Bio details Phase 3 path - Stock Titan Mon, 23 Feb 2026 08
- INMB Stock Receives Major Upgrade from Lucid Capital Markets | I - GuruFocus Wed, 11 Mar 2026 15
- INmune Bio (INMB) Could Find a Support Soon, Here's Why You Should Buy the Stock Now - Yahoo Finance hu, 06 Nov 2025 08
- INmune Bio stock falls after new Alzheimer’s trial data - Investing.com Mon, 01 Dec 2025 08
- INMB Stock Gained 3% Today – What Did The FDA Say About Its Alzheimer’s Trial? - Stocktwits hu, 12 Feb 2026 12
- Can INmune Bio (NASDAQ:INMB) Afford To Invest In Growth? - simplywall.st ue, 09 Dec 2025 08
- INmune Bio Stock: What's Left For Investors (NASDAQ:INMB) - Seeking Alpha Wed, 02 Jul 2025 07
- INmune Bio outlines 2026 regulatory path in shareholder letter - TipRanks ue, 27 Jan 2026 08
- Alzheimer’s trial signal and rare skin disease cell therapy at INmune Bio - Stock Titan ue, 27 Jan 2026 08
- INmune Bio (INMB) Loses 23.8% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner - Yahoo Finance Mon, 08 Sep 2025 07
- INmune Bio stock falls after stock offering (INMB:NASDAQ) - Seeking Alpha Fri, 27 Jun 2025 07
- INmune Bio's US$7.7m Market Cap Fall Books Insider Losses - simplywall.st ue, 26 Aug 2025 07
- Lucid Capital Markets upgrades INmune Bio stock rating on RDEB therapy - Investing.com Wed, 11 Mar 2026 11
- New trial data on systemic treatment for a painful skin disease - Stock Titan hu, 19 Feb 2026 08
- Is INmune Bio (NASDAQ:INMB) In A Good Position To Deliver On Growth Plans? - Yahoo Finance Sun, 10 Aug 2025 07
Insider Transactions
| Date | Shares | Value | Url | Text | Insider | Position | Transaction | Start Date | Ownership |
|---|---|---|---|---|---|---|---|---|---|
| 0 | 10000 | 52868 | — | Purchase at price 5.29 per share. | MOSS DAVID J. | Chief Financial Officer | — | 2024-09-30 00:00:00 | D |
| 1 | 15380 | 98048 | — | Purchase at price 6.38 per share. | TESI RAYMOND JOSEPH | Chief Executive Officer | — | 2024-09-12 00:00:00 | D |
| 2 | 7690 | 49024 | — | Purchase at price 6.38 per share. | MOSS DAVID J. | Chief Financial Officer | — | 2024-09-12 00:00:00 | D |
| 3 | 5000 | 36350 | — | Purchase at price 7.27 per share. | JUDA SCOTT | Director | — | 2024-06-25 00:00:00 | I |
| 4 | 18028 | 149993 | — | Purchase at price 8.32 per share. | TESI RAYMOND JOSEPH | Chief Executive Officer | — | 2024-04-19 00:00:00 | D |
| 5 | 18028 | 149993 | — | Purchase at price 8.32 per share. | MOSS DAVID J. | Chief Financial Officer | — | 2024-04-19 00:00:00 | D |
| 6 | 14423 | 119999 | — | Purchase at price 8.32 per share. | LOWDELL MARK WILLIAM | Officer and Beneficial Owner of more than 10% of a Class of Security | — | 2024-04-19 00:00:00 | D |
| 7 | 29603 | 246297 | — | Purchase at price 8.32 per share. | JUDA SCOTT | Director | — | 2024-04-19 00:00:00 | D |
| 8 | 18028 | 149993 | — | Stock Award(Grant) at price 8.32 per share. | TESI RAYMOND JOSEPH | Chief Executive Officer | — | 2024-04-19 00:00:00 | D |
| 9 | 18028 | 149993 | — | Stock Award(Grant) at price 8.32 per share. | MOSS DAVID J. | Chief Financial Officer | — | 2024-04-19 00:00:00 | D |
Financials
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| TaxEffectOfUnusualItems | 0.00 | 0.00 | 0.00 | 0.00 |
| TaxRateForCalcs | 0.00 | 0.00 | 0.00 | 0.00 |
| NormalizedEBITDA | -42.63M | -29.74M | -25.95M | -29.15M |
| NetIncomeFromContinuingOperationNetMinorityInterest | -42.08M | -30.01M | -27.30M | -30.34M |
| EBITDA | -42.63M | -29.74M | -25.95M | -29.15M |
| EBIT | -42.63M | -29.74M | -25.95M | -29.15M |
| NormalizedIncome | -42.08M | -30.01M | -27.30M | -30.34M |
| NetIncomeFromContinuingAndDiscontinuedOperation | -42.08M | -30.01M | -27.30M | -30.34M |
| TotalExpenses | 42.65M | 29.90M | 26.32M | 29.33M |
| TotalOperatingIncomeAsReported | -42.63M | -29.74M | -25.95M | -29.15M |
| DilutedAverageShares | 19.94M | 17.98M | 17.93M | 16.13M |
| BasicAverageShares | 19.94M | 17.98M | 17.93M | 16.13M |
| DilutedEPS | -2.11 | -1.67 | -1.52 | -1.88 |
| BasicEPS | -2.11 | -1.67 | -1.52 | -1.88 |
| DilutedNIAvailtoComStockholders | -42.08M | -30.01M | -27.30M | -30.34M |
| NetIncomeCommonStockholders | -42.08M | -30.01M | -27.30M | -30.34M |
| NetIncome | -42.08M | -30.01M | -27.30M | -30.34M |
| NetIncomeIncludingNoncontrollingInterests | -42.08M | -30.01M | -27.30M | -30.34M |
| NetIncomeContinuousOperations | -42.08M | -30.01M | -27.30M | -30.34M |
| PretaxIncome | -42.08M | -30.01M | -27.30M | -30.34M |
| OtherIncomeExpense | 553.00K | -267.00K | -1.35M | -1.19M |
| OtherNonOperatingIncomeExpenses | 553.00K | -267.00K | -1.35M | -1.19M |
| OperatingIncome | -42.63M | -29.74M | -25.95M | -29.15M |
| OperatingExpense | 42.65M | 29.90M | 26.32M | 29.33M |
| ResearchAndDevelopment | 33.17M | 20.27M | 17.07M | 20.54M |
| SellingGeneralAndAdministration | 9.48M | 9.62M | 9.26M | 8.79M |
| GeneralAndAdministrativeExpense | 9.48M | 9.62M | 9.26M | 8.79M |
| OtherGandA | 9.48M | 9.62M | 9.26M | 8.79M |
| TotalRevenue | 14.00K | 155.00K | 374.00K | 181.00K |
| OperatingRevenue | 14.00K | 155.00K | 374.00K | 181.00K |
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| OrdinarySharesNumber | 22.28M | 17.95M | 17.95M | 17.84M |
| ShareIssued | 22.28M | 17.95M | 17.95M | 17.84M |
| TotalDebt | 384.00K | 10.44M | 15.31M | 15.23M |
| TangibleBookValue | 15.58M | 21.62M | 43.59M | 63.71M |
| InvestedCapital | 32.10M | 48.06M | 74.80M | 94.68M |
| WorkingCapital | 15.44M | 21.48M | 53.76M | 78.25M |
| NetTangibleAssets | 15.58M | 21.62M | 43.59M | 63.71M |
| CapitalLeaseObligations | 384.00K | 516.00K | 613.00K | 776.00K |
| CommonStockEquity | 32.10M | 38.14M | 60.10M | 80.22M |
| TotalCapitalization | 32.10M | 38.14M | 69.80M | 94.68M |
| TotalEquityGrossMinorityInterest | 32.10M | 38.14M | 60.10M | 80.22M |
| StockholdersEquity | 32.10M | 38.14M | 60.10M | 80.22M |
| GainsLossesNotAffectingRetainedEarnings | -575.00K | -799.00K | -699.00K | 1.00K |
| OtherEquityAdjustments | -575.00K | -799.00K | -699.00K | 1.00K |
| RetainedEarnings | -163.10M | -121.02M | -91.01M | -63.72M |
| AdditionalPaidInCapital | 195.75M | 159.14M | 151.80M | 143.92M |
| CapitalStock | 22.00K | 817.00K | 18.00K | 18.00K |
| CommonStock | 22.00K | 817.00K | 18.00K | 18.00K |
| PreferredStock | 0.00 | 0.00 | 0.00 | 0.00 |
| TotalLiabilitiesNetMinorityInterest | 7.46M | 18.86M | 21.69M | 19.72M |
| TotalNonCurrentLiabilitiesNetMinorityInterest | 244.00K | 397.00K | 10.77M | 15.36M |
| NonCurrentAccruedExpenses | 0.00 | 550.00K | 199.00K | |
| LongTermDebtAndCapitalLeaseObligation | 244.00K | 397.00K | 10.22M | 15.16M |
| LongTermCapitalLeaseObligation | 244.00K | 397.00K | 526.00K | 704.00K |
| LongTermDebt | 9.70M | 14.46M | ||
| CurrentLiabilities | 7.22M | 18.46M | 10.92M | 4.36M |
| CurrentDeferredLiabilities | 517.00K | 489.00K | 616.00K | 474.00K |
| CurrentDebtAndCapitalLeaseObligation | 140.00K | 10.04M | 5.09M | 72.00K |
| CurrentCapitalLeaseObligation | 140.00K | 119.00K | 87.00K | 72.00K |
| CurrentDebt | 9.92M | 5.00M | ||
| OtherCurrentBorrowings | 9.92M | 5.00M | ||
| PayablesAndAccruedExpenses | 6.56M | 7.94M | 5.21M | 3.81M |
| Payables | 6.56M | 7.94M | 5.21M | 3.81M |
| AccountsPayable | 6.56M | 7.94M | 5.21M | 3.81M |
| TotalAssets | 39.56M | 57.00M | 81.80M | 99.94M |
| TotalNonCurrentAssets | 16.90M | 17.06M | 17.12M | 17.34M |
| OtherNonCurrentAssets | 79.00K | 131.00K | 99.00K | 99.00K |
| GoodwillAndOtherIntangibleAssets | 16.51M | 16.51M | 16.51M | 16.51M |
| OtherIntangibleAssets | 16.51M | 16.51M | 16.51M | 16.51M |
| NetPPE | 307.00K | 414.00K | 507.00K | 726.00K |
| GrossPPE | 307.00K | 414.00K | 507.00K | 726.00K |
| BuildingsAndImprovements | 307.00K | 414.00K | 507.00K | 726.00K |
| Properties | 0.00 | 0.00 | 0.00 | 0.00 |
| CurrentAssets | 22.66M | 39.94M | 64.67M | 82.61M |
| OtherCurrentAssets | 331.00K | 1.51M | 4.03M | 2.28M |
| PrepaidAssets | 0.00 | 142.00K | 34.00K | 14.00K |
| Receivables | 1.41M | 2.44M | 8.46M | 5.50M |
| TaxesReceivable | 1.41M | 2.44M | 8.46M | 5.50M |
| CashCashEquivalentsAndShortTermInvestments | 20.92M | 35.85M | 52.15M | 74.81M |
| CashAndCashEquivalents | 20.92M | 35.85M | 52.15M | 74.81M |
| CashFinancial | 74.81M |
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| FreeCashFlow | -33.36M | -11.98M | -22.69M | -43.50M |
| RepurchaseOfCapitalStock | 0.00 | |||
| RepaymentOfDebt | -10.00M | -5.00M | 0.00 | |
| IssuanceOfDebt | 0.00 | 14.95M | ||
| IssuanceOfCapitalStock | 27.79M | 775.00K | 699.00K | 80.25M |
| CapitalExpenditure | -15.00M | |||
| InterestPaidSupplementalData | 1.69M | 1.78M | 1.37M | 559.00K |
| IncomeTaxPaidSupplementalData | 0.00 | 0.00 | 0.00 | 0.00 |
| EndCashPosition | 20.92M | 35.85M | 52.15M | 74.81M |
| BeginningCashPosition | 35.85M | 52.15M | 74.81M | 21.97M |
| EffectOfExchangeRateChanges | 224.00K | -100.00K | -700.00K | -10.00K |
| ChangesInCash | -15.15M | -16.20M | -21.96M | 52.85M |
| FinancingCashFlow | 18.21M | -4.22M | 729.00K | 96.36M |
| CashFlowFromContinuingFinancingActivities | 18.21M | -4.22M | 729.00K | 96.36M |
| ProceedsFromStockOptionExercised | 422.00K | 0.00 | 30.00K | 1.15M |
| NetCommonStockIssuance | 27.79M | 775.00K | 699.00K | 80.25M |
| CommonStockPayments | 0.00 | |||
| CommonStockIssuance | 27.79M | 775.00K | 699.00K | 80.25M |
| NetIssuancePaymentsOfDebt | -10.00M | -5.00M | 0.00 | 14.95M |
| NetLongTermDebtIssuance | -10.00M | -5.00M | 0.00 | 14.95M |
| LongTermDebtPayments | -10.00M | -5.00M | 0.00 | |
| LongTermDebtIssuance | 0.00 | 14.95M | ||
| InvestingCashFlow | 0.00 | -15.00M | ||
| CashFlowFromContinuingInvestingActivities | 0.00 | -15.00M | ||
| NetIntangiblesPurchaseAndSale | 0.00 | -15.00M | ||
| PurchaseOfIntangibles | 0.00 | -15.00M | ||
| OperatingCashFlow | -33.36M | -11.98M | -22.69M | -28.50M |
| CashFlowFromContinuingOperatingActivities | -33.36M | -11.98M | -22.69M | -28.50M |
| ChangeInWorkingCapital | 1.04M | 10.44M | -2.86M | -3.09M |
| ChangeInOtherWorkingCapital | 28.00K | -127.00K | 142.00K | 284.00K |
| ChangeInOtherCurrentLiabilities | -25.00K | -4.00K | -33.00K | 46.00K |
| ChangeInOtherCurrentAssets | 52.00K | -32.00K | 0.00 | -99.00K |
| ChangeInPayablesAndAccruedExpense | -1.37M | 2.17M | 1.75M | 2.46M |
| ChangeInAccruedExpense | 0.00 | -550.00K | 351.00K | 199.00K |
| ChangeInPayable | -1.37M | 2.72M | 1.40M | 2.26M |
| ChangeInAccountPayable | -1.37M | 2.72M | 1.40M | 2.26M |
| ChangeInPrepaidAssets | 1.32M | 2.41M | -1.77M | -2.07M |
| ChangeInReceivables | 1.03M | 6.02M | -2.96M | -3.71M |
| OtherNonCashItems | 79.00K | 224.00K | 239.00K | 126.00K |
| StockBasedCompensation | 7.61M | 7.37M | 7.15M | 4.80M |
| AssetImpairmentCharge | 0.00 | 89.00K | 0.00 | |
| NetIncomeFromContinuingOperations | -42.08M | -30.01M | -27.30M | -30.34M |
SEC Filings
Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.
Public Trades for INMB
| Date | User | Broker | Pattern | Type | Position Size | Entry Price | Trade P&L | Status |
|---|